206 related articles for article (PubMed ID: 26194889)
1. Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty.
Heckmann M; Thermann H; Heckmann F
Hamostaseologie; 2015; 35(4):358-63. PubMed ID: 26194889
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
3. Influence of Fondaparinux Versus Nadroparin Calcium Thromboprophylaxis on Clinical Parameters Following Total Knee Arthroplasty.
Mihaljević Z; Dimnjaković D; Tripković B; Buljan M; Aljinović A; Delimar D; Bićanić G
Acta Clin Croat; 2016 Sep; 55(3):414-421. PubMed ID: 29045105
[TBL] [Abstract][Full Text] [Related]
4. Combination of Superficial and Deep Blocks with Rivaroxaban.
Chelly JE; Metais B; Schilling D; Luke C; Taormina D
Pain Med; 2015 Oct; 16(10):2024-30. PubMed ID: 26177810
[TBL] [Abstract][Full Text] [Related]
5. Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
van der Veen L; Segers M; van Raay JJ; Gerritsma-Bleeker CL; Brouwer RW; Veeger NJ; van Hulst M
BMJ Open; 2021 Jan; 11(1):e040336. PubMed ID: 33462096
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.
Wood RC; Stewart DW; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B
Pharmacotherapy; 2015 Jul; 35(7):663-9. PubMed ID: 26095331
[TBL] [Abstract][Full Text] [Related]
9. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
[TBL] [Abstract][Full Text] [Related]
10. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
11. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
[TBL] [Abstract][Full Text] [Related]
12. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients.
Gao X; Jin X; Huang R; Li Z; Zhang H; Fan P
BMC Surg; 2024 May; 24(1):162. PubMed ID: 38762739
[TBL] [Abstract][Full Text] [Related]
14. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
[TBL] [Abstract][Full Text] [Related]
15. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
17. The Effect of BMI and Gender on Bleeding Events when Rivaroxaban Is Administered for Thromboprophylaxis Following Total Hip and Total Knee Arthroplasty.
Krauss ES; Cronin M; Dengler N; Simonson BG; Altner K; Daly M; Segal A
Semin Thromb Hemost; 2019 Mar; 45(2):180-186. PubMed ID: 30566970
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
19. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
